Technical Analysis for FLGT - Fulgent Genetics, Inc.

Grade Last Price % Change Price Change
F 85.41 0.20% 0.17
FLGT closed up 0.2 percent on Friday, April 9, 2021, on 37 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical FLGT trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction 0.20%
Lower Bollinger Band Walk Weakness 0.20%
Wide Bands Range Expansion 0.20%
Down 3 Days in a Row Weakness 0.20%
Down 4 Days in a Row Weakness 0.20%
Lower Bollinger Band Touch Weakness 0.20%
Older End-of-Day Signals for FLGT ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Fulgent Genetics, Inc. Description

Fulgent Genetics, Inc. is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. As of December 31, 2015, the Company's test menu includes approximately 18,000 single-gene tests and over 200 pre-established, multi-gene, disease-specific panels that collectively test for approximately 7,500 genetic conditions, including various cancers, cardiovascular diseases and neurological disorders. The Company's gene probes are specifically engineered to generate genetic data that is optimized for its software, which enables to rapidly incorporate new genes into its test menu, develop new panels of disease-specific tests and customize tests for its customers.


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Biotechnology Cancers Genetics Cardiovascular Disease Medical Genetics Neurological Disorders Medical Tests Algorithms Vascular Diseases Cardiovascular Diseases Molecular Diagnostics Applied Genetics Urological Disorders Genetic Testing Adaptive Learning Qiagen Alternatives To Animal Testing

Is FLGT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 189.8899
52 Week Low 11.52
Average Volume 1,949,861
200-Day Moving Average 57.99
50-Day Moving Average 113.29
20-Day Moving Average 99.68
10-Day Moving Average 92.88
Average True Range 10.55
ADX 13.51
+DI 15.55
-DI 24.06
Chandelier Exit (Long, 3 ATRs ) 91.28
Chandelier Exit (Short, 3 ATRs ) 114.15
Upper Bollinger Band 117.58
Lower Bollinger Band 81.77
Percent B (%b) 0.1
BandWidth 35.92
MACD Line -5.23
MACD Signal Line -3.68
MACD Histogram -1.5542
Fundamentals Value
Market Cap 2.07 Billion
Num Shares 24.3 Million
EPS 2.14
Price-to-Earnings (P/E) Ratio 39.91
Price-to-Sales 7.56
Price-to-Book 5.95
PEG Ratio 1.32
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 91.62
Resistance 3 (R3) 91.34 88.99 90.59
Resistance 2 (R2) 88.99 87.41 89.13 90.24
Resistance 1 (R1) 87.20 86.43 88.10 87.48 89.89
Pivot Point 84.85 84.85 85.30 84.99 84.85
Support 1 (S1) 83.06 83.27 83.96 83.34 80.93
Support 2 (S2) 80.71 82.29 80.85 80.58
Support 3 (S3) 78.92 80.71 80.24
Support 4 (S4) 79.20